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0.02, p0.042), low vision in both eyes (difference:0.02, p0.041), and blindness
in both eyes (difference: 0.10, p0.0001) had lower EQ-5D score than those with-
out visual impairment. Singapore Indians with low vision in both eyes (difference:
0.03, p0.0081), low vision in one eye and blindness in the other eye (difference:
0.09, p0.0001), and blindness in both eyes (difference: 0.16, p0.0004) had
lower EQ-5D score than those without visual impairment. After adjusted for age,
gender and co-morbidities, none of the 5 eye conditions was associated with re-
duction in EQ-5D scores inMalays or Indians, except that Indianswith cataract had
lower EQ-5D scores than those without cataract (difference: 0.02, p0.0431).
CONCLUSIONS: Health burden is associated with visual impairment, but not with
the presence of the eye conditions. Vision problems pose more health burden to
Indians than Malays in Singapore.
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OBJECTIVES: To evaluate the effect of aqueous extract of Boswellia serrata Roxb
oleo gumon urinary electrolytes, pH and diuresis in normal albino rats.METHODS:
Oleo gumweighing 500g was soaked in hot boiling water (1L) at room temperature
for 3 days with occasional shaking. Filtrate was evaporated on rotary evaporator
under reduced pressure (760 mmHg) to a thick, semi-solid pasty mass of dark
drown color that was completely solubilized in both distilled water and normal
saline for in-vitro and in-vivo experimentation. Phytochemical analysis was car-
ried out for alkaloids, saponins, anthraquinones, flavanoids and tannins. For in-
vivo activity, five groups of with six animals in each were administered normal
saline (10ml/Kg, i.p.), Furosemide (10mg/kg) and crude extracts of Boswellia sarrata
(10, 30 and 50mg/kg of body weight), respectively. Toxicological effect of plant was
undertaken in rats at a dose of 3000mg/kg. Data was expressed asmean SEM and
analyzed using Graph Pad Prism (Graph PAD, San Diego, USA). Student t-test was
applied for data analysis. p values 0.05 were considered significant. RESULTS:
Phytochemical screening of Boswellia serrata Roxb confirmed the presence of sa-
ponins and flavonoids. Furosemide induced significant diuresis and electrolytes
(Na&K) excretionwhile plant extracts increased urinary output and electrolytes
excretion in a dose-dependentmanner. Diuretic index of test groupswere1.36, 2.06
and 2.9, respectively while, Lipschitz value also confirmed diuretic activity in dose
dependent manner. Urinary pH remained unchanged during the course of the
study whereas, no lethality was observed at the dose of 3000mg/kg.
CONCLUSIONS: Aqueous Boswellia serrata oleo gum extracts administered partic-
ularly at the dose of 50mg/kg significantly induced water and electrolytes with no
signs of toxicity.
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OBJECTIVES: To assess economic burden associated with hemodialysis (HD) and
continuous ambulatory peritoneal dialysis (CAPD) among patients with end-stage
renal disease (ESRD) and treated in a tertiary hospital in China. METHODS: From
Sept 2004 to Jan 2005, adult patients on HD or CAPD for at least 6 months were
recruited. Resource utilization and costs were collected by medical records review
and patient survey. The economic burden was divided into direct costs including
medical (dialysis, drugs, lab, and inpatient) and nonmedical (transportation, hired
caregivers, and special nutritional products) and indirect costs due to productivity
loss (human capital approach). The annualized costs expressed in 2010 Yuan(¥)
were analyzed using Wilcoxon test and General Linear Model with gamma distri-
bution and log link. RESULTS: Eighty-six patients [50 on CAPD and 36 on standard
HD (3x4-hour weekly)] were included for the analysis, with 55% male and a mean
age of 57.715.6 years. No differences were found in age, sex, education, payment
method, income, originating disease, haemoglobin level, and dialysis time be-
tween HD and CAPD. Mean(SD)/Median of annual medical expenses were
¥91,476(42,935)/¥82,478 for HD and ¥68,898(11,698)/¥68,191 for CAPD (p0.0001);
nonmedical direct expenses were ¥5,883(4,256)/¥4,780 for HD and ¥3,041(3,835)/
¥1,300 for CAPD (p0.0001). No differencewas found in indirect costs [¥3,167 (6,992)
for HD and ¥5,064 (8,354) for CAPD (p0.3)]. Total annual costs were
¥100,403(44,419)/¥90,262 for HD and ¥79,859(22,210)/¥77,681 for CAPD (p0.001).
Controlling for key factors/covariates, HD patients incurred 16% higher total cost
compared to CAPD patients (p0.01). Patients with younger age (p0.005), public
health insurance (p0.0001), or originating disease of diabetes (p0.03) incurred
higher total costs compared to their counterparts, respectively. CONCLUSIONS:
Patients received HD incurred more direct costs compared to patients undergoing
CAPD. The findings of this study may help understand the disease burden and
establish cost-effective treatment modalities in ESRD from Chinese societal per-
spective.
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OBJECTIVES: To evaluate the annual health expenditure (AHE) in patients with
neurogenic detrusor overactivity (NDO) after spinal cord injury (SCI). METHODS:
Data containing 2 million randomly sampled individuals from the National Health
Insurance Research Database (NHIRD) in Taiwan were used. Patients with emer-
gency department visits or hospitalizations for SCI defined by ICD-9 codes 806.X
and 952.X between 2006 and 2008 were retrieved. NDOwas defined by: 1) diagnosis
defined by ICD-9 codes 596.5 and 788.3 (excluding 596.53, paralysis of bladder); 2)
pharmacological treatment for neurogenic voiding dysfunction and urinary symp-
toms such as alpha blockers, antimuscarinic agents, and cholinergic agents; and 3)
procedures such as indwelling or intermittent catheterization defined byNHI codes
47,013C and 47,014C. All patients were followed for one year. The total AHE, as well
as three subcategories, hospital, outpatient, and pharmacological treatment re-
lated cost were calculated respectively. Covariates including patient’s demograph-
ics, hospital length of stay, concomitant medications, and comorbid conditions
were considered in the final linear regression to compare the AHE between NDO
and non-NDO group. RESULTS: A total of 941 eligible individuals with SCI were
identified from 2006 to 2008, of whom 165 (17.5%) were NDO cases with amean age
of 54 and consisting of 64%male. The total AHEwas 494,325 (499,259) and 108,529
(147,287) N.T. dollars inNDO and non-NDO group, respectively. After adjusting by
regression model, the total AHE was higher in NDO (364,611; SE21,082;
p0.001) than non-NDO group. Higher AHE was also shown in NDO in each sub-
category when comparing with non-NDO. CONCLUSIONS: A significant impact on
the financial burden of NDO was shown in this study. Higher AHE associated with
NDOmay also reflective of the higher severity of SCI or other comorbid conditions.
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OBJECTIVES:To estimate the total economic burden of both peritoneal dialysis and
renal anemia treatment in China. METHODS: Eight medical centers with regular
follow-up system for peritoneal dialysis patients in 6 provinces were selected for
prospective observation research. Inclusion and exclusion criteria were set down
before the study through the discussion with clinical experts. Patients had been
recruited in the study since July of 2011. Patient baseline characteristics, treatment
and expenditure for both outpatient and inpatient during 3-months follow-up du-
ration were recorded. Direct medical costs included fee for registration and ser-
vices, medical examination, drugs andmedical consumable materials. Direct non-
medical costs included transportation fee and nursing fee. Off-work days were
collected to estimate indirect costs.RESULTS:A total of 149 patientswith records of
703 outpatient visits and 19 inpatient stays were collected. Mean age of patients is
50.9with averagely 3.47 years of peritoneal dialysis treatment and 3.35 years of EPO
treatment. The average frequencywas 1.41 visits inmedical centers permonth and
1.23 visits in community health centers. The average cost of EPO was CNY1,518
(US$241) per month with average dosage of 16443IU. Total economic burden per
peritoneal dialysis patient was CNY9,756 (US$1,549) per month, including
CNY9,163 (US$1,454) for direct medical costs, CNY210 (US$33) for direct non-med-
ical costs and CNY383 (US$61) for indirect costs. The share of total economic bur-
den related to GDP per capita ranged from 1.3 times to 6.4 times in 6 sampling
provinces. CONCLUSIONS: The total economic burden of both peritoneal dialysis
and renal anemia treatment seems relatively high, which needs more attention
from the government and society.
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OBJECTIVES: This study evaluated the clinical and economic impacts of clinical
pharmacy education (CPE) on infection management among patients with chronic
kidney disease (CKD) stage 4 and 5 in Haji Adam Malik (HAM) hospital, Indonesia.
METHODS: A quasi-experimental economic evaluation comparing CPE impact on
six-months CKD mortality was conducted based on payer perspective. The exper-
imental group (n63) received care by health care providers that were given CPE on
DRPs and dose adjustment. The control group (n80) was based on the historical
cohort of patients that received care before the CPE. Measure of clinical outcome
applied in this study was number of lives saved/100 patients treated. Cost-effec-
tiveness (CE) ratios for stage 4 and 5 CKD patients without CPE and with CPE,
incremental cost effectiveness ratios (ICERs) for stage 4 and 5 CKD patients were
analyzed. RESULTS: Lives saved (%) in the treatment of CKD without CPE: CKD
stage 4, 78.57; CKD stage 5, 57.58. Lives saved (%) in the treatment of CKDwith CPE:
CKD stage 4, 88.89; CKD stage 5, 65.45. Cost- effectiveness ratios for stage 4 without
and with CPEs were Rp3,593,295.97 and Rp3,348,733.27, respectively. Cost-effec-
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